• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Pfizer studies duration of serologic response

March 1, 2004

Orlando, Fla.-Pfizer Animal Health recently unveiled its findings on the duration of serologic response to its Vanguard canine vaccine with or without Leptospira bacterin fraction. And the results may be surprising.

Orlando, Fla.-Pfizer Animal Health recently unveiled its findings on the duration of serologic response to its Vanguard canine vaccine with or without Leptospira bacterin fraction. And the results may be surprising.

The Pfizer study shows that its Vanguard vaccines demonstrated protection for some dogs up to four years.

Pfizer explains the study was meant to shed light on the issue of duration of immunity, especially considering last year's American Animal Hospital Association canine vaccine protocols calling for three-year vaccination intervals for parvovirus, adenovirus-2, distemper and rabies (depending on state law).

Advertisement

Dr. Ed Kanara, director of Pfizer's technical services, explains, "Pfizer is a science-based company, and we wanted to understand this whole issue of duration of immunity with our vaccines."

The study, which was published in the Journal of the American Veterinary Medical Association's (JAVMA) Jan. 1 issue by Mouzin DE, Lorenzen MJ, Haworth JD, et al, entitled "Duration of serologic response to five viral antigens in dogs," looked at serologic response levels to canine adenovirus-1 (CAV-1), canine adenovirus-2 (CAV-2), canine distemper virus (CDV), canine parvovirus (CPV) and canine parainfluenza virus (CPIV). Kanara adds that the study only focused on Pfizer vaccines.

The study looked at 322 clinically normal dogs from veterinary clinics in the United States and Canada. The dogs were of both sexes, either sexually intact or neutered and at least 2 years of age. Serum samples were tested at Cornell University's Veterinary Diagnostic Laboratory. The company reports that serologic responses were seen in 98.4 percent of dogs for CAV-1, 99 percent for CAV-2, 98.1 percent for CDV, 98.1 percent for CPV and 100 percent CPIV. "Similar response rates were seen for low-risk and high-risk dogs (categorized based on a questionnaire)," the company reports. "Responders to each viral antigen were observed for all time periods, including up to more than four years after the last vaccination."

Inside the results

Kanara says that the data may help practitioners in making vaccination decisions with clients and in setting up appropriate vaccination intervals, however, it is under the discretion of the attending veterinarian.

What to do?

The company says, "Pfizer believes there is no universal protocol. The attending veterinarian continues to be the best person to determine the appropriate protocol for each patient in conjunction with the pet owner."


Advertisement

Latest News

Partners for Health Pets and VHMA collaboration publish white paper

Vetstoria releases its Fill Rate platform

What's new with the "Dentistry Lane" across the veterinary profession?

Meet the BlackDVM Network

View More Latest News
Advertisement